phentermine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
anorexics 2140 122-09-8

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • phentermine
  • duromine
  • normephentermine
  • phentermine hydrochloride
  • phentermine HCl
  • phentermine resin complex
A central nervous system stimulant and sympathomimetic with actions and uses similar to those of DEXTROAMPHETAMINE. It has been used most frequently in the treatment of obesity.
  • Molecular weight: 149.24
  • Formula: C10H15N
  • CLOGP: 2.14
  • LIPINSKI: 0
  • HAC: 1
  • HDO: 1
  • TPSA: 26.02
  • ALOGS: -2.29
  • ROTB: 2
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
15 mg O

ADMET properties:

PropertyValueReference
MRTD (Maximum Recommended Therapeutic Daily Dose) 4.19 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BDDCS (Biopharmaceutical Drug Disposition Classification System) 3 Hosey CM, Chan R, Benet LZ
S (Water solubility) 2 mg/mL Bocci G, Oprea TI, Benet LZ

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
kinase-safety-class ACVR2A,ACVR2B,AKT1,AKT2,AKT3,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK5,CDK9,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,ITK,JAK2,JAK3,MAP3K21,MAP3K7,MAPK12,MAPK7,MET,NTRK2,PDK2,PDK4,PIM2,PRKCD,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TGFBR1 39
kinase-selectivity-class AKT2,AKT3,AXL,GRK2,PDK4 5
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pld-class Phospholipidosis risk class (1 = positive, 0 = negative) 0 Moderate 0.65

Approvals:

DateAgencyCompanyOrphan
May 4, 1959 FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Cholecystitis chronic 173.51 16.35 56 8691 9770 90609930
Dermatitis atopic 80.08 16.35 41 8706 23431 90596269
Gallbladder disorder 77.60 16.35 38 8709 19765 90599935
Emotional distress 75.63 16.35 46 8701 36616 90583084
Stress cardiomyopathy 75.36 16.35 33 8714 13322 90606378
Drug abuse 67.37 16.35 59 8688 82288 90537412
Arteriospasm coronary 66.16 16.35 23 8724 5027 90614673
Carotid artery dissection 64.80 16.35 12 8735 195 90619505
Colitis ischaemic 64.80 16.35 29 8718 12317 90607383
Completed suicide 63.42 16.35 74 8673 144984 90474716
Anxiety 57.12 16.35 105 8642 309667 90310033
Subarachnoid haemorrhage 51.75 16.35 28 8719 17876 90601824
Phospholipidosis 49.95 16.35 10 8737 249 90619451
Product dose omission issue 46.53 16.35 93 8654 291594 90328106
Cholelithiasis 45.72 16.35 39 8708 52467 90567233
Serotonin syndrome 38.96 16.35 31 8716 37856 90581844
Pulmonary embolism 38.67 16.35 55 8692 130765 90488935
Psoriasis 37.74 16.35 58 8689 147696 90472004
Substance-induced psychotic disorder 37.13 16.35 13 8734 2899 90616801
Rhabdomyolysis 32.73 16.35 32 8715 51224 90568476
Encephalomalacia 31.99 16.35 8 8739 555 90619145
Anhedonia 30.61 16.35 17 8730 11414 90608286
Injury 30.33 16.35 62 8685 197287 90422413
Spinal cord infarction 30.10 16.35 7 8740 357 90619343
Device dislocation 28.66 16.35 24 8723 31458 90588242
Deep vein thrombosis 27.77 16.35 39 8708 91581 90528119
Drug intolerance 27.50 16.35 5 8742 447586 90172114
Biliary dyskinesia 27.11 16.35 10 8737 2589 90617111
Infusion related reaction 27.07 16.35 4 8743 416776 90202924
Pain 26.92 16.35 176 8571 996165 89623535
Cardiomyopathy 23.97 16.35 18 8729 20188 90599512
Joint swelling 22.86 16.35 10 8737 503290 90116410
Psychotic disorder 22.80 16.35 21 8726 31209 90588491
Acute myocardial infarction 22.68 16.35 22 8725 34868 90584832
Suspected suicide 22.31 16.35 13 8734 9555 90610145
Hepatic enzyme increased 22.22 16.35 4 8743 360732 90258968
Renal vein thrombosis 21.82 16.35 6 8741 603 90619097
Drug interaction 21.46 16.35 67 8680 276386 90343314
Glossodynia 21.09 16.35 3 8744 321776 90297924
Nausea 20.82 16.35 180 8567 1110136 89509564
Subacute cutaneous lupus erythematosus 20.68 16.35 9 8738 3573 90616127
Arthropathy 20.62 16.35 5 8742 366237 90253463
Pseudomembranous colitis 20.02 16.35 9 8738 3859 90615841
Treatment failure 19.53 16.35 3 8744 303925 90315775
Complication of device insertion 18.75 16.35 12 8735 10424 90609276
Palpitations 18.72 16.35 41 8706 136687 90483013
Injection site pain 18.27 16.35 47 8700 173652 90446048
Abnormal dreams 17.92 16.35 12 8735 11245 90608455
Medical device discomfort 17.88 16.35 7 8740 2129 90617571
Amyloidosis 17.54 16.35 6 8741 1250 90618450
Retinal artery occlusion 17.47 16.35 7 8740 2264 90617436
Right ventricular dysfunction 17.20 16.35 7 8740 2357 90617343
Systemic lupus erythematosus 16.72 16.35 7 8740 361889 90257811
Cardio-respiratory arrest 16.40 16.35 25 8722 63115 90556585

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug abuse 62.57 28.49 37 1078 104734 42515486
Glomerulonephritis minimal lesion 28.91 28.49 6 1109 680 42619540

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Cholecystitis chronic 156.78 17.25 48 7930 9452 110571869
Drug abuse 102.66 17.25 92 7886 177319 110404002
Stress cardiomyopathy 92.97 17.25 37 7941 15769 110565552
Completed suicide 83.65 17.25 95 7883 242286 110339035
Emotional distress 69.00 17.25 42 7936 44805 110536516
Arteriospasm coronary 63.07 17.25 24 7954 9076 110572245
Gallbladder disorder 61.10 17.25 30 7948 20999 110560322
Colitis ischaemic 59.70 17.25 28 7950 17722 110563599
Carotid artery dissection 59.62 17.25 12 7966 415 110580906
Dermatitis atopic 55.59 17.25 30 7948 25511 110555810
Phospholipidosis 50.25 17.25 10 7968 326 110580995
Product dose omission issue 47.48 17.25 84 7894 321698 110259623
Subarachnoid haemorrhage 46.15 17.25 28 7950 29674 110551647
Injury 42.61 17.25 58 7920 177207 110404114
Anxiety 38.48 17.25 80 7898 344998 110236323
Pain 38.42 17.25 153 7825 954802 109626519
Psoriasis 35.46 17.25 47 7931 139946 110441375
Cholelithiasis 34.86 17.25 32 7946 63390 110517931
Substance-induced psychotic disorder 32.94 17.25 13 7965 5411 110575910
Device dislocation 32.40 17.25 23 7955 31681 110549640
Serotonin syndrome 30.88 17.25 29 7949 59124 110522197
Pulmonary embolism 30.33 17.25 55 7923 214419 110366902
Deep vein thrombosis 29.49 17.25 43 7935 139844 110441477
Toxicity to various agents 28.82 17.25 88 7890 480467 110100854
Rhabdomyolysis 28.32 17.25 39 7939 120362 110460959
Respiratory arrest 27.44 17.25 27 7951 58272 110523049
Encephalomalacia 26.53 17.25 8 7970 1494 110579827
Cardio-respiratory arrest 26.46 17.25 37 7941 115799 110465522
Suspected suicide 25.35 17.25 15 7963 15184 110566137
Spinal cord infarction 24.45 17.25 7 7971 1091 110580230
Biliary dyskinesia 22.77 17.25 8 7970 2413 110578908
Anhedonia 22.57 17.25 14 7964 15414 110565907
Complication of device insertion 20.97 17.25 11 7967 8827 110572494
Vanishing bile duct syndrome 20.68 17.25 8 7970 3160 110578161
Cardiomyopathy 20.56 17.25 18 7960 33507 110547814
Subacute cutaneous lupus erythematosus 20.33 17.25 9 7969 4985 110576336
Right ventricular dysfunction 20.31 17.25 8 7970 3315 110578006
Glomerulonephritis minimal lesion 20.08 17.25 6 7972 1085 110580236
Renal vein thrombosis 19.90 17.25 6 7972 1119 110580202
Scleroderma 18.28 17.25 9 7969 6332 110574989
Pseudomembranous colitis 18.21 17.25 9 7969 6382 110574939
Acute myocardial infarction 18.01 17.25 26 7952 83751 110497570
Injection site swelling 17.60 17.25 22 7956 61768 110519553
Psychotic disorder 17.58 17.25 20 7958 50917 110530404
Dihydrotestosterone increased 17.49 17.25 3 7975 42 110581279
Drug intolerance 17.40 17.25 4 7974 406508 110174813

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC A08AA01 ALIMENTARY TRACT AND METABOLISM
ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS
ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS
Centrally acting antiobesity products
ATC A08AA51 ALIMENTARY TRACT AND METABOLISM
ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS
ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS
Centrally acting antiobesity products
FDA PE N0000175372 Appetite Suppression
FDA EPC N0000175423 Sympathomimetic Amine Anorectic
MeSH PA D000697 Central Nervous System Stimulants
MeSH PA D001067 Appetite Depressants
MeSH PA D013566 Sympathomimetics
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D018663 Adrenergic Agents
MeSH PA D019440 Anti-Obesity Agents
FDA PE N0000175651 Increased Sympathetic Activity
CHEBI has role CHEBI:35337 central nervous system stimulant
CHEBI has role CHEBI:35470 central nervous system drug
CHEBI has role CHEBI:35524 sympathomimetic agent
CHEBI has role CHEBI:35526 hypoglycemic agent
CHEBI has role CHEBI:37962 adrenergic agent
CHEBI has role CHEBI:48560 dopaminergic agent
CHEBI has role CHEBI:50507 appetite depressant
CHEBI has role CHEBI:74518 anti-obesity agent
CHEBI has role CHEBI:231911 renoprotective agent

Related Drugs by ATC class:

A08AA Centrally acting antiobesity products 15 drugs
bupropioncathineclobenzorexdexfenfluraminediethylpropionephedrineetilamfetaminefenfluraminelorcaserinmazindolmefenorexnaltrexone show all 15 →

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Low blood pressure indication 45007003
Obesity indication 414916001 DOID:9970
Prevention of Hypotension During Spinal Anesthesia indication
Hypotension Secondary to Spinal Anesthesia indication
Heart valve disorder contraindication 368009 DOID:4079
Alcoholism contraindication 7200002
Glaucoma contraindication 23986001 DOID:1686
Feeling agitated contraindication 24199005
Hyperthyroidism contraindication 34486009 DOID:7998
Hypertensive disorder contraindication 38341003 DOID:10763
Mild pre-eclampsia contraindication 41114007
Conduction disorder of the heart contraindication 44808001
Diabetes mellitus type 1 contraindication 46635009 DOID:9744
Disorder of cardiovascular system contraindication 49601007 DOID:1287
Substance abuse contraindication 66214007
Psychotic disorder contraindication 69322001
Pulmonary hypertension contraindication 70995007 DOID:6432
Secondary glaucoma contraindication 95717004
Angina pectoris contraindication 194828000
Edema contraindication 267038008
Syncope contraindication 271594007
Arteriosclerosis obliterans contraindication 361133006 DOID:5160
Hypertensive urgency contraindication 443482000




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 9.92 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
EQ 11.25MG BASE;69MG QSYMIA VIVUS LLC N022580 July 17, 2012 RX CAPSULE, EXTENDED RELEASE ORAL 8895057 June 9, 2028 FOR CHRONIC WEIGHT MANAGEMENT IN ADULTS WITH BMI >=30 KG/M2 OR BMI >=27 KG/M2 WITH A WEIGHT-RELATED COMORBIDITY, AND PATIENTS AGE 12-17 WITH BMI >=25 KG/M2 IN THE 95TH PERCENTILE OR GREATER (STANDARDIZED FOR AGE AND SEX)
EQ 11.25MG BASE;69MG QSYMIA VIVUS LLC N022580 July 17, 2012 RX CAPSULE, EXTENDED RELEASE ORAL 9011906 June 9, 2028 FOR CHRONIC WEIGHT MANAGEMENT IN ADULTS WITH BMI >=30 KG/M2 OR BMI >=27 KG/M2 WITH A WEIGHT-RELATED COMORBIDITY, AND PATIENTS AGE 12-17 WITH BMI >=25 KG/M2 IN THE 95TH PERCENTILE OR GREATER (STANDARDIZED FOR AGE AND SEX)
EQ 15MG BASE;92MG QSYMIA VIVUS LLC N022580 July 17, 2012 RX CAPSULE, EXTENDED RELEASE ORAL 8895057 June 9, 2028 FOR CHRONIC WEIGHT MANAGEMENT IN ADULTS WITH BMI >=30 KG/M2 OR BMI >=27 KG/M2 WITH A WEIGHT-RELATED COMORBIDITY, AND PATIENTS AGE 12-17 WITH BMI >=25 KG/M2 IN THE 95TH PERCENTILE OR GREATER (STANDARDIZED FOR AGE AND SEX)
EQ 15MG BASE;92MG QSYMIA VIVUS LLC N022580 July 17, 2012 RX CAPSULE, EXTENDED RELEASE ORAL 9011906 June 9, 2028 FOR CHRONIC WEIGHT MANAGEMENT IN ADULTS WITH BMI >=30 KG/M2 OR BMI >=27 KG/M2 WITH A WEIGHT-RELATED COMORBIDITY, AND PATIENTS AGE 12-17 WITH BMI >=25 KG/M2 IN THE 95TH PERCENTILE OR GREATER (STANDARDIZED FOR AGE AND SEX)
EQ 3.75MG BASE;23MG QSYMIA VIVUS LLC N022580 July 17, 2012 RX CAPSULE, EXTENDED RELEASE ORAL 8895057 June 9, 2028 FOR CHRONIC WEIGHT MANAGEMENT IN ADULTS WITH BMI >=30 KG/M2 OR BMI >=27 KG/M2 WITH A WEIGHT-RELATED COMORBIDITY, AND PATIENTS AGE 12-17 WITH BMI >=25 KG/M2 IN THE 95TH PERCENTILE OR GREATER (STANDARDIZED FOR AGE AND SEX)
EQ 3.75MG BASE;23MG QSYMIA VIVUS LLC N022580 July 17, 2012 RX CAPSULE, EXTENDED RELEASE ORAL 9011906 June 9, 2028 FOR CHRONIC WEIGHT MANAGEMENT IN ADULTS WITH BMI >=30 KG/M2 OR BMI >=27 KG/M2 WITH A WEIGHT-RELATED COMORBIDITY, AND PATIENTS AGE 12-17 WITH BMI >=25 KG/M2 IN THE 95TH PERCENTILE OR GREATER (STANDARDIZED FOR AGE AND SEX)
EQ 7.5MG BASE;46MG QSYMIA VIVUS LLC N022580 July 17, 2012 RX CAPSULE, EXTENDED RELEASE ORAL 8895057 June 9, 2028 FOR CHRONIC WEIGHT MANAGEMENT IN ADULTS WITH BMI >=30 KG/M2 OR BMI >=27 KG/M2 WITH A WEIGHT-RELATED COMORBIDITY, AND PATIENTS AGE 12-17 WITH BMI >=25 KG/M2 IN THE 95TH PERCENTILE OR GREATER (STANDARDIZED FOR AGE AND SEX)
EQ 7.5MG BASE;46MG QSYMIA VIVUS LLC N022580 July 17, 2012 RX CAPSULE, EXTENDED RELEASE ORAL 9011906 June 9, 2028 FOR CHRONIC WEIGHT MANAGEMENT IN ADULTS WITH BMI >=30 KG/M2 OR BMI >=27 KG/M2 WITH A WEIGHT-RELATED COMORBIDITY, AND PATIENTS AGE 12-17 WITH BMI >=25 KG/M2 IN THE 95TH PERCENTILE OR GREATER (STANDARDIZED FOR AGE AND SEX)
EQ 11.25MG BASE;69MG QSYMIA VIVUS LLC N022580 July 17, 2012 RX CAPSULE, EXTENDED RELEASE ORAL 8580299 June 14, 2029 FOR CHRONIC WEIGHT MANAGEMENT IN ADULTS WITH BMI >=30 KG/M2, AND PATIENTS AGE 12-17 WITH BMI >=30 KG/M2 AND IN THE 95TH PERCENTILE OR GREATER (STANDARDIZED FOR AGE AND SEX), EACH HAVING A WEIGHT-RELATED COMORBIDITY
EQ 15MG BASE;92MG QSYMIA VIVUS LLC N022580 July 17, 2012 RX CAPSULE, EXTENDED RELEASE ORAL 8580299 June 14, 2029 FOR CHRONIC WEIGHT MANAGEMENT IN ADULTS WITH BMI >=30 KG/M2, AND PATIENTS AGE 12-17 WITH BMI >=30 KG/M2 AND IN THE 95TH PERCENTILE OR GREATER (STANDARDIZED FOR AGE AND SEX), EACH HAVING A WEIGHT-RELATED COMORBIDITY
EQ 3.75MG BASE;23MG QSYMIA VIVUS LLC N022580 July 17, 2012 RX CAPSULE, EXTENDED RELEASE ORAL 8580299 June 14, 2029 FOR CHRONIC WEIGHT MANAGEMENT IN ADULTS WITH BMI >=30 KG/M2, AND PATIENTS AGE 12-17 WITH BMI >=30 KG/M2 AND IN THE 95TH PERCENTILE OR GREATER (STANDARDIZED FOR AGE AND SEX), EACH HAVING A WEIGHT-RELATED COMORBIDITY
EQ 7.5MG BASE;46MG QSYMIA VIVUS LLC N022580 July 17, 2012 RX CAPSULE, EXTENDED RELEASE ORAL 8580299 June 14, 2029 FOR CHRONIC WEIGHT MANAGEMENT IN ADULTS WITH BMI >=30 KG/M2, AND PATIENTS AGE 12-17 WITH BMI >=30 KG/M2 AND IN THE 95TH PERCENTILE OR GREATER (STANDARDIZED FOR AGE AND SEX), EACH HAVING A WEIGHT-RELATED COMORBIDITY

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
EQ 11.25MG BASE;69MG QSYMIA VIVUS LLC N022580 July 17, 2012 RX CAPSULE, EXTENDED RELEASE ORAL Sept. 13, 2027 INFORMATION ADDED TO THE LABELING TO DESCRIBE A CLINICAL STUDY
EQ 15MG BASE;92MG QSYMIA VIVUS LLC N022580 July 17, 2012 RX CAPSULE, EXTENDED RELEASE ORAL Sept. 13, 2027 INFORMATION ADDED TO THE LABELING TO DESCRIBE A CLINICAL STUDY
EQ 3.75MG BASE;23MG QSYMIA VIVUS LLC N022580 July 17, 2012 RX CAPSULE, EXTENDED RELEASE ORAL Sept. 13, 2027 INFORMATION ADDED TO THE LABELING TO DESCRIBE A CLINICAL STUDY
EQ 7.5MG BASE;46MG QSYMIA VIVUS LLC N022580 July 17, 2012 RX CAPSULE, EXTENDED RELEASE ORAL Sept. 13, 2027 INFORMATION ADDED TO THE LABELING TO DESCRIBE A CLINICAL STUDY

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Sodium-dependent noradrenaline transporter Transporter INHIBITOR WOMBAT-PK CHEMBL
Sodium-dependent dopamine transporter Transporter Ki 5.80 WOMBAT-PK

External reference:

IDSource
4019891 VUID
N0000147976 NUI
D05458 KEGG_DRUG
1197-21-3 SECONDARY_CAS_RN
4018166 VANDF
4018167 VANDF
4019891 VANDF
C0031447 UMLSCUI
CHEBI:8080 CHEBI
CHEMBL1574 ChEMBL_ID
DB00191 DRUGBANK_ID
CHEMBL1200912 ChEMBL_ID
D010645 MESH_DESCRIPTOR_UI
4771 PUBCHEM_CID
1064 INN_ID
7269 IUPHAR_LIGAND_ID
C045TQL4WP UNII
221138 RXNORM
1294 MMSL
41147 MMSL
5278 MMSL
5279 MMSL
d00806 MMSL
001864 NDDF
001865 NDDF
001866 NDDF
373343009 SNOMEDCT_US
426428004 SNOMEDCT_US
53480001 SNOMEDCT_US
6394006 SNOMEDCT_US
C045TQL4WP INXIGHT DRUGS

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Phentermine and topiramate HUMAN PRESCRIPTION DRUG LABEL 2 0480-2299 CAPSULE, EXTENDED RELEASE 11.25 mg ORAL ANDA 29 sections
Phentermine and topiramate HUMAN PRESCRIPTION DRUG LABEL 2 0480-3295 CAPSULE, EXTENDED RELEASE 15 mg ORAL ANDA 29 sections
Phentermine and topiramate HUMAN PRESCRIPTION DRUG LABEL 2 0480-3296 CAPSULE, EXTENDED RELEASE 7.50 mg ORAL ANDA 29 sections
Phentermine and topiramate HUMAN PRESCRIPTION DRUG LABEL 2 0480-3297 CAPSULE, EXTENDED RELEASE 3.75 mg ORAL ANDA 29 sections
Phentermine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 10544-098 CAPSULE 30 mg ORAL ANDA 26 sections
Phentermine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 10544-099 CAPSULE 15 mg ORAL ANDA 9 sections
Phentermine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 10544-116 TABLET 37.50 mg ORAL ANDA 9 sections
Phentermine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 10544-552 TABLET 30 mg ORAL ANDA 31 sections
Phentermine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 10544-592 CAPSULE 37.50 mg ORAL ANDA 9 sections
Phentermine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 10544-593 CAPSULE 30 mg ORAL ANDA 19 sections
Phentermine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 10544-602 TABLET 37.50 mg ORAL ANDA 19 sections
Phentermine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 10544-620 CAPSULE 30 mg ORAL ANDA 9 sections
LOMAIRA HUMAN PRESCRIPTION DRUG LABEL 1 10702-001 TABLET 8 mg ORAL ANDA 17 sections
Phentermine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 10702-025 TABLET 37.50 mg ORAL ANDA 25 sections
Phentermine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 10702-026 CAPSULE 15 mg ORAL ANDA 29 sections
Phentermine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 10702-027 CAPSULE 30 mg ORAL ANDA 29 sections
Phentermine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 10702-028 CAPSULE 30 mg ORAL ANDA 29 sections
Phentermine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 10702-029 CAPSULE 37.50 mg ORAL ANDA 25 sections
Phentermine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 10702-067 TABLET 8 mg ORAL ANDA 17 sections
Phentermine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 11534-157 CAPSULE 15 mg ORAL ANDA 28 sections
Phentermine hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 11534-159 CAPSULE 37.50 mg ORAL ANDA 29 sections
Phentermine hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 11534-160 TABLET 37.50 mg ORAL ANDA 29 sections
Phentermine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 11534-176 CAPSULE 30 mg ORAL ANDA 28 sections
Phentermine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 12634-516 CAPSULE 30 mg ORAL ANDA 9 sections
Phentermine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 12634-547 CAPSULE 30 mg ORAL ANDA 31 sections
Phentermine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 12634-552 CAPSULE 15 mg ORAL ANDA 9 sections
Phentermine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 12634-687 TABLET 37.50 mg ORAL ANDA 31 sections
PHENTERMINE HYDROCHLORIDE Human Prescription Drug Label 1 13107-061 TABLET 37.50 mg ORAL ANDA 29 sections
Phentermine Human Prescription Drug Label 1 13107-105 CAPSULE 15 mg ORAL ANDA 29 sections
Phentermine Human Prescription Drug Label 1 13107-106 CAPSULE 30 mg ORAL ANDA 29 sections